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ABSTRAK
Jangkitan Clostridium difficile (CDI) menyebabkan cirit-birit ringan hingga tenat 
dan kolitis pseudomembran di kalangan pesakit yang mempunyai pendedahan 
antibiotik terdahulu. Walaupun CDI berleluasa di seluruh dunia, data epidemiologi 
berkaitan CDI secara relatifnya adalah sedikit di Malaysia. Kajian ini bertujuan 
menentukan prevalen dan insiden CDI di Pusat Perubatan Universiti Kebangsaan 
Malaysia (PPUKM). Spesimen tinja tidak berbentuk daripada 147 pesakit yang 
disyaki menghidap CDI dari 1 November 2011 hingga 31 Oktober 2012 telah 
digunakan dalam kajian ini. Kehadiran toksin A dan/atau B C. difficile dikesan 
dengan menggunakan kit imunokromatografi komersial (Wampole™ Tox A/B 
QuikChek). Data pengamatan dikumpul daripada rekod kesihatan pesakit bagi 
mendapatkan ciri-ciri demografi dan klinikal. Keseluruhan prevalen dan insiden 
CDI di PPUKM masing-masing adalah 6.1% dan 5.2 kes per 10 000 hari-pesakit. 
Di kalangan sembilan orang pesakit CDI, 77.8% adalah lelaki dan 55.6% berbangsa 
Cina. CDI paling kerap berlaku di wad perubatan (88.9%). Median umur adalah 60 
tahun dan median tempoh inap di hospital adalah 13 hari. Majoriti (88.9%) pesakit 
CDI telah menerima antibiotik lapan minggu sebelum mendapat CDI. Penisilin-
perencat-beta-laktamase merupakan antibiotik yang paling kerap digunakan. Lima 
(55.6%) pesakit CDI telah menerima ubatan penindas asid. Kadar kematian di 
hospital adalah 22.2%. Kesimpulannya, prevalen dan insiden CDI dalam institusi 
ini secara relatifnya adalah rendah dan berlaku secara sporadik.
Kata kunci: jangkitan Clostridium difficile, ciri-ciri demografi, prevalen, insiden, 
Malaysia
ABSTRACT
Clostridium difficile infection (CDI) causes mild to severe diarrhoea and 
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pseudomembranous colitis in patients who had prior antibiotic exposure. 
Despite CDI being prevalent worldwide, its epidemiological data is scanty in 
Malaysia. This study aimed to determine the prevalence and incidence of CDI at 
Universiti Kebangsaan Malaysia Medical Centre (UKMMC). Stool specimens from 
147-suspected CDI patients were obtained from 1 November 2011 until 31 October 
2012. The presence of C. difficile toxin A and/or B were detected using a commercial 
immunochromatographic kit (Wampole™ Tox A/B Quik Chek). Surveillance data 
was collected from patients’ medical records to establish the demographic and 
clinical characteristics. The overall prevalence and incidence of CDI in UKMMC was 
6.1% and 5.2 cases per 10 000 patient-days, respectively. Among nine CDI patients, 
77.8% were males and 55.6% were Chinese. CDI was most common in medical 
wards (88.9%). The median age was 60 years and the median length of hospital stay 
was 13 days. Majority (88.9%) of CDI patients received antibiotics eight weeks prior 
to CDI. Penicillin-beta-lactamase inhibitors were the most common antecedent 
antibiotics. Five (55.6%) CDI patients received acid suppressant medications. The 
in-hospital mortality rate was 22.2%. In conclusion, the prevalence and incidence 
of CDI at UKMMC is relatively low and occurs sporadically. 
Keywords: Clostridium difficile infection, demographic characteristics, prevalence, 
incidence, Malaysia
States, it affects over three million 
diarrhoeal and colitis patients, annually 
(Schroeder 2005). In Asia Pacific region, 
CDI prevalence had increased over the 
years. In Singapore for instance, the 
prevalence increased from 1.49 cases 
per 10,000 patient-days in year 2001 to 
6.64 cases per 10,000 patient-days in 
year 2006 (Lim et al. 2008). In Malaysia, 
three out of seven CDI cases resulted 
in death from pseudomembranous 
colitis (Parasakthi et al.1988). Recently, 
it has been observed that incidence of 
CDI cases in northern eastern coast of 
Malaysia is 13.7% (Hassan et al. 2012).
 Although CDI had been extensively 
investigated in most western and 
Asia Pacific region, there has been 
no established data on it at Universiti 
Kebangsaan Malaysia Medical Centre 
(UKMMC). The aim of the present 
study was to determine the incidence, 
INTRODUCTION
Clostridium difficile is recognized as 
a significant nosocomial pathogen 
responsible for antibiotic-associated 
diarrhoea in most hospitals worldwide 
(Bartlett 1996; Hall & O’Toole 1935; 
McFarland 1998). It is an opportunistic, 
gram-positive, rod-shaped, spore-
forming anaerobic bacterium known 
to be one of the minor colonic floras. 
The diagnosis of Clostridium difficile 
infection (CDI) is based on the presence 
of diarrhoea and  stool test positive 
for toxigenic C. difficile or its toxin or 
colonoscopy or hisptopathologic findings 
demonstrating pseudomembranous 
colitis (Cohen et al. 2010).
 The prevalence of CDI varies with 
hospital populations. In the United 
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prevalence and epidemiological and 
clinical characteristics of CDI among 
hospitalized patients at UKMMC.
MATERIALS AND METHODS
STUDY DESIGN
The cross-sectional study was carried 
out in Bacteriology Laboratory, 
Department of Diagnostic Laboratory 
Services from November 2011 until 
October 2012. All unformed stool 
specimens from patients suspected 
with CDI as sent by clinicians were 
included. Duplicate specimens from 
the same patient within a 10-day period 
were excluded from this study (Peterson 
& Robicsek 2009). The diagnosis of 
CDI was confirmed by presence of C. 
difficile toxins in stool.
CLOSTRIDIUM DIFFICILE TOXIN 
DETECTION
Clostridium difficile toxins A and/
or B were detected by a commercial 
kit (Wampole™ Tox A/B QuikChek, 
Techlab, USA), having 90.2% sensitivity 
and 99.7% specificity (manufacturer’s 
insert). This rapid membrane enzyme 
immunoassay uses specific antibodies 
to detect toxins A and/or B of C. 
difficile in stool. The procedure steps 
were followed as directed. Presence of 
blue line in control and test reaction 
window within a 10-minute reading 
time was interpreted as positive result; 
indicating the presence of C. difficile A 
and/or B toxin.
DEMOGRAPHIC AND CLINICAL 
DATA
Data of C. difficile toxin-positive cases 
that were collected from patients’ 
medical records included length of 
hospitalization, onset of diarrhoea, 
antibiotics used two months prior to 
diarrhoeal onset, nasogastric tube 
usage, immunosuppressive therapy, 
recent surgical intervention, underlying 
disease and others. 
 Monthly data on inpatient-days were 
obtained from Medical Informatics 
Department to calculate the incidence 
of CDI. The study received approval 
from the Research and Ethics Committee 
of Universiti Kebangsaan Malaysia 
(ERGS/1/2011/SKK/UKM/03/29).
STATISTICAL ANALYSIS
Statistical analyses were performed 
using the Statistical Package for the 
Social Sciences (SPSS) software version 
15.0 (SPSS, Inc, USA). Categorical 
variables and continuous variables were 
described as number (percentage) and 
median (IQR or range), respectively. 
RESULTS
A total of 147 stool specimens were 
collected throughout the one-year 
study period. Nine of the 147 specimens 
were C. difficile toxin-positive and 
categorized as CDI (Figure 1). The overall 
prevalence of CDI was 6.1%. Monthly 
incidence of CDI was presented (Figure 
2). Cases of CDI occurred sporadically 
during December-January and May-
June. However, there were no CDI in 
the remaining months. The overall 
incidence throughout the study period 
was 5.2 cases per 10 000 patient-days. 
The average monthly incidence rate 
was 0.4 per 10 000 patient-days.
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 Demographic and clinical 
characteristics of nine CDI cases were 
summarized (Table 1). It was revealed 
from the table that male to female ratio is 
7:2, and affects both Chinese and Malay. 
The median patient age is 60 years (IQR: 
57-67.5 years, range: 25-74). Majority of 
cases are from medical wards. 
 Two (22.2%) of the diarrhoeal cases 
occurred prior to the hospitalisation 
and confirmed CDI within 48 hours of 
admission. The remaining seven cases 
acquired CDI during hospitalisation. 
Median duration between admissions 
to CDI onset was six days (IQR: 6-12 
days, range: 5-29 days). Median time to 
CDI detection was nine days (IQR 6-13 
days, range: 6-32 days).
 One (11.1%) of the nine cases did 
not have antibiotics therapy eight 
weeks prior to diarrhoea onset. In the 
remaining eight cases, a combined total 
of 22 courses of antibiotics (median: 2, 
range: 1-5 courses) and 106 days of 
antibiotic therapy (median: 13.5, range: 
5-21 days) were implicated. Penicillin-
beta lactamase inhibitors group (Table 
2) was the most common antibiotics 
used; accounting for 49 out of 106 days. 
Cephalosporins and carbapenems 
accounted for seven and six out of 106 
days, respectively.
Figure 1: Prevalence of Clostridium difficile infection at UKMMC
Figure 2: Monthly incidence rates of Clostridium difficile infection at UKMMC
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Table 1: Demographic and clinical characteristics of Clostridium difficile infection at 
UKMMC
 
Characteristics Frequency (%)
Sex Male 7 (77.8)
Female 2 (22.2)
Male:Female 3.5:1
Race Chinese 5 (55.6)
Malay 4 (44.4)
Indian & others 0 (0)
Age (years) Median (IQR) 60 (57-67.5)
Range 25-74
> 65 years 6 (66.7)
Location Medical 8 (88.9)
Intensive Care Unit 1 (11.1)
Diarrheal Onset Before hospitalisation 2 (22.2)
During hospitalisation 7 (77.8)
Admission to CDI Onset (days) Median (IQR) 6 (6-12)
Range 5-29
Admission to CDI Detection (days) Median (IQR) 9 (6-13)
Range 6-32
Recent Antibiotics (courses) 0 1(11.1)
1 3 (33.3)
2 5 (55.5)
Median (Range) 2 (1-5)
Duration of Antibiotic Therapy 
(days)
Median (Range) 13.5 (5-21)
Prior Hospitalisation Yes 4 (44.4)
No 3 (33.3)
No data 2 (22.2)
Length of Current Hospitalisation 
(days)
Median (IQR) 13 (8-18)
Range 7-39
Comorbidity 1 underlying disease 1 (11.1)
≥≥2 underlying diseases 8 (88.9)
Acid-suppressing Medications Yes 5 (55.6)
No 4 (44.4)
Recent Therapeutic Intervention Nasogastric tube 4 (44.4)
OGDS 1 (11.1)
Chemotherapy 0 (0)
Colonoscopy 0 (0)
GIT surgery 0 (0)
In-hospital Mortality Rate 2 (22.2)
IQR: Interquartile Range
OGDS: Oesophagogastroduodenoscopy
GIT: Gastrointestinal
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 Records on prior hospitalisation 
were available in seven CDI cases. 
Four (57.1%) of these cases had 
hospitalization 12 weeks prior to the 
current admission. There were no 
recurrent CDI found in this study. The 
median length of hospitalisation for 
CDI was 13 days (IQR: 8-18 days, range: 
7-39 days). Most cases had two or more 
underlying diseases. Five (55.6%) of 
the cases were on acid-suppressing 
medication. Throughout this period, 
majority of CDI was mild to moderate. 
None of the cases was treated with oral 
metronidazole or oral vancomycin. 
Hospital mortality rate among CDI 
cases was 22.2%.
DISCUSSION
The overall prevalence of CDI at 
UKMMC was 6.1% and the overall 
incidence was 5.2 cases per 10 000 
patient-days. This data is comparable 
with the data from southern Taiwan and 
Singapore (Chung et al. 2010; Lim et al. 
2008). Our prevalence was substantially 
lower than that of Canadian hospitals 
(Simor et al. 2013) and northeastern 
part of Peninsular Malaysia (Hassan et 
al. 2012). The monthly incidence rate 
indicates that CDI is not endemic in our 
institution.   
 The difference in prevalence and 
incidence can be explained by (1) 
difference in hospital categories 
(2) diversity in study population (3) 
variable study designs and sampling 
methods and (4) prior medications 
and therapeutic intervention (Chung 
et al. 2010).  In our institution, low 
prevalence of CDI could be due to lack 
of awareness to CDI (Jamal et al. 2010). 
Lack of suspicion affects the yield of 
sampling and reduces the chances to 
diagnose CDI. In addition, the use of 
less sensitive technique instead of tissue 
culture cytotoxin assay and toxigenic C. 
difficile culture (Alcalá et al. 2008) may 
also explain for this finding. Hence, we 
started with another study involving 
several sensitive techniques to validate 
the current findings.
 Major risk factors for CDI are 
hospitalisation, older age and 
history of antibiotic usage (Bartlett 
2008). Underlying disease has been 
reported as another major risk factor 
for nosocomial CDI (Kyne et al. 
2002).  In our study, we observed that 
majority of CDI cases had diarrhoea 
onset during hospitalisation and six 
Table 2: Antibiotics implicated in Clostridium difficile infection
Antibiotic Class Days
Penicillin-Beta-Lactamase Inhibitor 49
Macrolide 14
Quinolone 8
Sulphonamide 8
Glycopeptide 8
Cephalosporin 7
Carbapenem 6
Nitroimidazole 4
Penicillin 2
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(66.7%) of these cases were patients 
older than 65 years old. In addition, 
eight (88.9%) patients had antibiotics 
therapy within eight weeks before 
diarrhoea onset and all nine cases 
had at least one underlying disease. 
Unlike in other studies, tube feeding 
and oesophagogastroduodenoscopy 
(OGDS) were not common therapeutic 
interventions among CDI cases in our 
institution (Bliss et al. 1998; Thibault 
et al. 1991). More than half of CDI 
cases had received acid-suppressing 
medications within 8 weeks before the 
diarrhoeal onset. This finding is similar 
to that reported by Aslam & Musher 
(2006). Our study did not demonstrate 
significant association between CDI 
and the established risk factors (data 
not shown) because of small number 
of cases studied over a short period. To 
identify the risk factors in our institution, 
a case-control study involving larger 
samples would be appropriate.
 For hospital-acquired CDI the 
median duration of diarrhoea onset was 
six days and median time to detection 
was nine days. Our study had shorter 
median time for detection as majority 
of the cases had earlier diarrhoea-onset 
between five to six days. Previous study 
by Forster et al. (2012) showed a longer 
time for detection of hospital-acquired 
CDI as the study focused on cases 
occurring after day-7 hospitalisation. 
 It was observed that penicillin-beta-
lactamase inhibitors were the most 
common antibiotics received prior to 
CDI onset. This finding is similar to 
the previous study by Lee et al. (2012). 
Unlike in other studies, cephalosporins 
were not the common antecedent 
antibiotics (Kim et al. 2014; Lai et al. 
2013). We also found that most of the 
cases were not on ‘low risk’ antibiotics 
prior to CDI onset. To reduce CDI 
incidence, Talpaert et al. (2011) 
recommended the usage of ‘low risk’ 
antibiotics for empirical treatment of 
common infections among hospitalized 
patients.
 The median length of hospitalization 
for CDI cases was 13 days. Our finding 
is consistent with other studies. Few 
studies found that CDI is more likely 
to occur among patients who are 
hospitalized for seven days or more 
(Dumyati et al. 2012; Lee et al. 2012; 
Manian et al. 2007). We found that 
majority of the cases were mild to 
moderate and did not require oral 
metronidazole or oral vancomycin. 
Two cases that succumbed to death 
were related to their underlying 
primary diseases. However, in one 
case, the patient died one day after 
CDI was diagnosed. The death could 
be attributed to the complications 
associated with CDI.
 A continuous CDI surveillance is 
useful to illustrate future incidence 
trend, disease recurrence and changes 
in our local clinico-epidemiology 
pattern. Based on this observational 
study, physicians should keep CDI in 
consideration in all cases of diarrhoea 
that had antibiotic therapy and/or 
acid suppressing medications in the 
preceding eight weeks. 
CONCLUSION
In conclusion, the incidence and 
prevalence of CDI in our institution 
were relatively low. The cases occurred 
sporadically and were mild to moderate 
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in severity. Our preliminary data has 
important clinical significance that 
conveys strong message: community 
and hospital-acquired CDI do exist 
at our institution. A continuous 
surveillance and regular antibiotic audit 
may help curb CDI from spreading 
further. 
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